ERBB2 and cancer: For instance, the monoclonal antibody trastuzumab inhibits HER2 homodimerization by binding to the extracellular domain of HER2 to prevent its activation, leading to the antibody-dependent cytotoxicity of HER2+ cancer cells [5].